Open for Enrollment Soon
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

RECAST study - Clinical Trial

What is the Purpose of this Study?

This study looks at different treatments for early breast cancer (DCIS). It has four parts:

- Screening: Doctors do tests to see if you can join.

- Treatment: You’re randomly placed in a group to get either standard medicine or a new treatment.

- Surgery Check: After 3 months, doctors decide if surgery is needed.

- Follow-Up: You’ll get check-ups for up to 5 years, and yearly follow-ups for 10 years.

Treatments may include pills, hormone therapy, or small pellets under the skin. You’ll also have tests like MRIs, mammograms, and blood samples.

What is the Condition Being Studied?

Adults with DCIS (ductal carcinoma in situ) and hormone receptor (HR +) breast cancer

Who Can Participate in the Study?

Who can join this study:

- Adults with a type of early breast cancer called DCIS that is hormone receptor-positive (HR+).

- People who were already diagnosed with HR+ DCIS, even if it shows tiny signs of spreading.

- People who had a breast MRI within the last 2 months and a mammogram within the last 4 months to check the cancer.

Age Group
Adults

What is Involved?

Doctors are doing a study to see if people with a type of early breast cancer called DCIS can be safely treated with medicine instead of surgery. They want to know if using drug therapy and regular breast scans can help avoid surgery while still keeping patients healthy.

Study Details

Full Title
DCIS: RECAST Trial - Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a breast cancer prevention pilot study
Principal Investigator
Ton Wang, MD, MS
Surgical Oncologist
Protocol Number
IRB: PRO00117651
NCT: NCT06075953
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment Soon
Support Duke Health research or honor a loved one with a tribute gift.